Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN2810 (cemiplimab) long-term follow-up and re-treatment
NCT02520245Phase 1Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of cemiplimab in malignant neoplasms (advanced stage), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Overall Survival up to 8 years and Safety measured by Adverse Events up to 8 years. Planned start Aug 2015; status: withdrawn.
02
Drugs
cemiplimab
03
Conditions
malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT02520245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520245.